“My faith is with technology and with psychedelics. Politics aren’t going to take us much further. ” – Terence McKenna September 20th, 2021 I dig Terence McKenna, but…
Taylor Gavinchuk
Episode 2 Earlier this year Mindmed (MNMD.Q) co-founder JR Rahn went on an epic selling spree, selling nearly 90% of his holdings without telling the public why until days…
It seems like every few days I stumble across a new name in the psychedelics industry I hadn’t heard before. Usually smaller deals just getting off the ground. But,…
$10b Reddit, the 19th most visited website on the internet has murmurs surrounding its potential IPO this year. On August 12th Reddit confirmed with TechCrunch that it raised…
“In business, cash is oxygen” – Gary Vaynerchuk Psychedelics is a cash-intensive business. Earlier in the week, I wrote about how clinical trials alone cost companies tens, sometimes…
Studying clinical studies For many psychedelics companies, clinical trials are the most expensive part of their business model and the reason they need to raise so much capital. Finding…
-65% Over the summer Hexo (HEXO.N) shares have dropped from $7.18 USD to $2.54 US, a 65% decrease. The company’s market cap currently sits at $387.9 million CAD despite…
Black swan It’s no surprise that Delta (DAL.C) is down 21% since the delta variant became dominant. While Delta has taken a worse beating than the other major airlines,…
Jamaica, farewell At first glance, I didn’t know what to make of Aion Therapeutics (AION.C). There are a few moving parts, it’s a psychedelics/cannabis hybrid deal with a focus…
Debt is good, sometimes Debt is an important factor when sussing out a company to invest in. Knowing why the company has taken out debt, how much debt they’ve…